Last reviewed · How we verify
Topical Hydrogen Peroxide
Topical hydrogen peroxide acts as an antimicrobial and oxidizing agent that kills bacteria and other microorganisms through reactive oxygen species generation.
Topical hydrogen peroxide acts as an antimicrobial and oxidizing agent that kills bacteria and other microorganisms through reactive oxygen species generation. Used for Minor cuts, scrapes, and wounds, Oral rinse for minor mouth irritation and gum inflammation, Ear canal cleaning and cerumen removal.
At a glance
| Generic name | Topical Hydrogen Peroxide |
|---|---|
| Also known as | Crystacide 1% |
| Sponsor | University of Toronto |
| Drug class | Antimicrobial agent / Antiseptic |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Wound Care |
| Phase | FDA-approved |
Mechanism of action
Hydrogen peroxide penetrates microbial cell membranes and generates free radicals that damage cellular components, DNA, and proteins, leading to cell death. It also mechanically cleanses wounds by releasing oxygen bubbles that help remove debris and necrotic tissue. The antimicrobial effect is broad-spectrum, affecting bacteria, fungi, and some viruses.
Approved indications
- Minor cuts, scrapes, and wounds
- Oral rinse for minor mouth irritation and gum inflammation
- Ear canal cleaning and cerumen removal
Common side effects
- Local irritation or burning sensation
- Temporary bleaching of skin or hair
- Allergic contact dermatitis
Key clinical trials
- Bioadhesive Film of Acmella Oleracea (Jambu) in the Reduction of Post-bleaching Dental Sensitivity Caused by Bleaching With 35% Hydrogen Peroxide. (PHASE3)
- DMT310-009 Topical in the Treatment of Acne Vulgaris (PHASE3)
- Effect of an Experimental Cannabidiol Gel on Tooth Sensitivity (PHASE1)
- IDEAL: Efficacy of Porcine Placental Extracellular Matrix Augmented Plus Standard of Care (SOC) Versus SOC Alone for the Management of Diabetic Foot Ulcers (NA)
- Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II) (PHASE3)
- Randomized Controlled Clinical Trial of Hyperthermia and Hydrogen Peroxide 3% in the Treatment of Cutaneous Warts (NA)
- A New Clinical Use of Ferumoxytol Nanoparticles: An Antibiofilm Treatment (PHASE4)
- Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |